A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Conditions:   Relapsed Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Richter Syndrome;   MYC Amplification;   MYC Overexpression;   MYC Translocation Intervention:   Drug: VIP152 Sponsor:   Vincerx Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials